Jiaqiang Cai - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Jiaqiang Cai

Co-founder and CSO and Co-Chief Executive Officer Medilink Therapeutics

Seminars

Monday 12th October 2026

Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs

2:00 pm

Exploring how Topo1 and Topo1-ADCs elicit immunogenic cell stress in vivo through the induction of cellular senescence
Delineating the host immune cell requirements for Topo1-induced immunogenicity
Identifying biomarkers of immunogenic cell stress mediated by Topo1 ADCs

Jiaqiang (JQ) Cai - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure